Recent Updates
Recently added Catalysts
IMVT Positive Sentiment

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Thursday, September 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunovant, Inc. will host an investor webcast on September 9, 2024, to provide updates on its Graves' Disease program. The webcast will present new epidemiologic data, results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program. This event signifies the company's ongoing commitment to development in autoimmune diseases and its innovative approach in the field.
Price reaction · baseline $30.69 (2024-09-04 close) · hit after-hours · 1 other IMVT headline(s) in the window, move may be shared
day 0 close
+9.5%
day 1 · peak
+10.9%
day 3
-3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is providing a timely update on its Graves' Disease program.
  • The update includes promising new epidemiologic data and findings from its Phase 2 study.
  • The company is positioning itself as a leader in anti-FcRn technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
7.3%
average across 5 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
IMVT-1402
Phase 3 · Generalized Myasthenia Gravis

Full Press Release Details

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program.
The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD.
The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Chief Financial Officer
Source: Immunovant Inc.

Frequently Asked Questions

When is Immunovant's investor webcast on Graves’ Disease program?

The investor webcast is scheduled for September 9th at 8:00 a.m. ET.

What will be discussed during the Immunovant webcast?

The webcast will cover new epidemiologic data, Phase 2 study results, and the IMVT-1402 program.

How can I access the Immunovant webcast?

You can register for the event or view it on Immunovant's website under News & Events.

What does Immunovant specialize in?

Immunovant focuses on developing therapies for autoimmune diseases using anti-FcRn technology.

ShareAdd on Google
Tags: IMVT Viatris Investor Conferences Healthcare Immunovant Graves' Disease batoclimab IMVT-1402 clinical-stage
Last updated: Sep 5, 2024

Biotech snapshot

Cash runway
$798M liquidity · $41M/mo burn
~19 mo
Low dilution risk
Lead asset
IMVT-1402Phase 3
Generalized Myasthenia Gravis →

Catalyst track record

+85%
best trade around IMVT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for IMVT.

See every catalyst's timing & PoA →